Navigation Links
MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
Date:11/10/2011

DALLAS, November 10, 2011 /PRNewswire/ --

The report "Lung Cancer Drugs Market in G7 Countries (2005 - 2020) [ http://www.marketsandmarkets.com/Market-Reports/lung-cancer-drugs-market-508.html ]" analyzes and studies the major market drivers, restraints, and opportunities in North America, and Europe.

Browse in-depth TOC on Lung Cancer Drugs Market in G7 Countries (2005 - 2020).

Get Free 10% customization on reports
http://www.marketsandmarkets.com/Market-Reports/lung-cancer-drugs-market-508.html

Lung cancer is the most common form of cancer in terms of incidence and number of deaths. It is a disease wherein the cell lining of lung tissue grows uncontrollably and leads to the formation of tumor. There are two main types of lung cancer; small cell lung cancer that accounts for about 20% and non-small cell lung cancer (NSCLC) that accounts for about 80% of the total lung cancers.

The lung cancer drugs market was valued at around $4 billion in 2010 and is expected to reach about $13 billion by 2020, growing at a CAGR of 13.5% from 2015 to 2020. The market was dominated by drugs such as Avastin, Iressa, Gemzar, and Tarceva in 2010. However, by 2020, the market is expected to be dominated by talactoferrin (Agennix), an immunomodulatory drug; followed by Xalkori (Pfizer), and by ARQ 197 (ArQule/Daiichi Sankyo).

According to WHO, lung cancer prevalence is expected to grow in the emerging markets such as the BRIC countries and other Asian and African markets due to an increase in the use of tobacco products. Tobacco is the primary cause of around 80% of all lung cancers. The other causes such as radon gas exposure, asbestos can be causative factor for devel
'/>"/>

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
2. MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014
3. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014
4. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
5. MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014
6. MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014
7. MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015
8. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
9. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
10. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
11. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... SAN DIEGO , Aug. 31, 2015 ... drug development company announces that the Company,s lead antibody, ... subject of five separate presentations during the upcoming World ... Hawaii September 2-5, 2015. Researchers from the ... (MSK) will present results on the use of MabVax,s ...
(Date:8/31/2015)...  For people with Down syndrome, news from ... company, located in the Science + Technology Park at ... therapies yet for people with Down syndrome and other chromosome ... syndrome and Edwards syndrome aneuploidies in human cell cultures, ... Elixirgen plans to develop this technology into a treatment ...
(Date:8/31/2015)... 2015 FLX Bio, Inc., a biopharmaceutical company ... immunotherapies, announced today that it has appointed Brian ... William Ho , M.D., Ph.D., as Chief Medical ... team led by veterans of Flexus Biosciences, Inc., FLX,s ... Officer; Jay Powers , Ph.D., Vice President, Drug ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment ... is the first commercially available new FDA approved system in the last 14 years, ... 92%, the high Amenorrhea (zero bleeding) rate of 66%, the high Patient Satisfaction rate ...
Breaking Biology Technology:MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4New Down syndrome therapy discovered 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... ... new partner and sponsor in Life Line Screening. The two companies aim to ... abdominal aortic aneurysm and , peripheral arterial disease screening . Life Line ... its customers can easily donate money to the foundation. , ...
... , SAN DIEGO, Dec. 9 ... top-line efficacy and safety results from the Tulip PETAL Study ... proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in ... data from the Tulip PETAL Study are consistent with what ...
... , Nashville, Tenn., Dec. 9 Cumberland Pharmaceuticals ... entered into an exclusive agreement with DB Pharm Korea Co. ... ( ibuprofen ) Injection in South Korea. Designed to treat pain ... U.S. Food and Drug Administration and launched by Cumberland in the ...
Cached Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4
(Date:8/20/2015)... Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... joined The Smart Card Alliance and the EMV Migration ... and the Smart Card Alliance Latin America (SCALA) Chapter ... peers and thought leaders promoting adoption of smart card ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... Studies show the incidence of diabetes in dogs has increased ... Missouri veterinarians have changed the way veterinarians treat diabetes in ... humans. Dogs are susceptible to type 1, insulin-dependent diabetes. ... because their bodies do not produce enough insulin, a hormone ...
... around the world have forced many species to the brink ... multiple causes that are still not fully understood, researchers conclude ... causative factor is often missing the larger picture, they said, ... don,t consider the totality of causes or could even ...
... April 25, 2011 - Call them the Jason Bournes of ... secret agents, some bacteria avoid antibiotic treatments by essentially shutting ... says Thomas Wood, professor in the Artie McFerrin Department of ... elaborate survival mechanism is explained in the online April edition ...
Cached Biology News:MU researchers pioneer animal diabetes treatment 2Catastrophic amphibian declines have multiple causes, no simple solution 2Catastrophic amphibian declines have multiple causes, no simple solution 3'Going off the grid' helps some bacteria hide from antibiotics 2'Going off the grid' helps some bacteria hide from antibiotics 3